In addition, nivolumab + ipilimumab combination therapy has recently been granted an accelerated approval as a treatment for BRAF V600 wild-type unresectable or metastatic melanoma in the US based on findings from the CheckMate-069 [24, 46]. The gene discussed is BRAF; the disease is metastatic melanoma.